Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for orofacial tardive dyskinesia
NL-OMON24924Active, not recruiting
- Sponsor
- Ipsen
- Start
- Feb 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Single-blind trial of botulinum toxin type A in tardive dyskinesia (TD), sponsored by Ipsen. Started Feb 2004; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NL-OMON24924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24924.